Clene Inc Stock In The News
| CLNN Stock | USD 4.49 0.26 5.47% |
Our overall analysis of Clene's news coverage and content from conventional and social sources shows investors' bearish mood towards Clene Inc. The specific impact of Clene news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Clene's overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Clene headlines in addition to utilizing other, more conventional financial analysis modules. Check out Clene Backtesting and Clene Hype Analysis.
Clene |
Clene Inc Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Clene and other traded companies coverage with news coverage. We help investors stay connected with Clene headlines for the 1st of February to make an informed investment decision based on correlating the impacts of news items on Clene Stock performance. Please note that trading solely based on the Clene Inc hype is not for everyone as timely availability and quick action are needed to avoid losses.
Clene stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Clene earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Clene that are available to investors today. That information is available publicly through Clene media outlets and privately through word of mouth or via Clene internal channels. However, regardless of the origin, that massive amount of Clene data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Clene news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Clene relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Clene's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Clene alpha.
Clene Largest EPS Surprises
Earnings surprises can significantly impact Clene's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-08 | 2024-03-31 | -0.08 | -0.09 | -0.01 | 12 | ||
2024-03-13 | 2023-12-31 | -0.07 | -0.06 | 0.01 | 14 | ||
2022-05-09 | 2022-03-31 | -0.19 | -0.21 | -0.02 | 10 | ||
2022-11-07 | 2022-09-30 | -0.22 | -0.17 | 0.05 | 22 | ||
2021-08-10 | 2021-06-30 | -0.15 | -0.21 | -0.06 | 40 | ||
2023-11-07 | 2023-09-30 | -0.09 | -0.02 | 0.07 | 77 |
Clene Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Clene Inc Stock. Current markets are slightly bearish. About 51% of major world exchanges and indexes are down. See today's market update for more information.
30th of January 2025
Acquisition by Zhang Xiaoyan Michelle of 964 shares of Ikena Oncology at 2.1462 subject to... at MacroaxisInsider
27th of January 2025
Investors in Molecular Partners have unfortunately lost 81 percent over the last three yea... at news.google.com
22nd of January 2025
Acquisition by Michael LaCascia of 126000 shares of Foghorn Therapeutics at 4.37 subject t... at MacroaxisInsider
17th of January 2025
12 Health Care Stocks Moving In Fridays Pre-Market Session - Benzinga at news.google.com
17th of January 2025
Disposition of 7447 shares by Ralph Brandenberger of Nkarta at 2.2 subject to Rule 16b-3 at news.google.com
17th of January 2025
Sensei Biotherapeutics, Inc. Short Interest Update at thelincolnianonline.com
14th of January 2025
Werewolf Therapeutics SWOT analysis stock faces challenges amid pipeline progress at investing.com
14th of January 2025
Immunome Stock Price Down 7.1 percent - Heres Why - MarketBeat at news.google.com
13th of January 2025
IBN Coverage Clene Paves Cash Runway to Advance CNM-Au8 for ALS at finance.yahoo.com
8th of January 2025
Champions Oncology, Inc.s market cap up US26m last week, benefiting both private equity fi... at simplywall.st
8th of January 2025
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sl... at gurufocus.com
7th of January 2025
Acquisition by Matsuda Kazuko of 300000 shares of MediciNova at 1.52 subject to Rule 16b-3 at MacroaxisInsider
7th of January 2025
Resources Top 5 Kalamazoo leads as Mallina West gold assays loom at stockhead.com.au
6th of January 2025
Acquisition by Daniel Hicklin of 592690 shares of Werewolf Therapeutics at 1.56 subject to... at MacroaxisInsider
6th of January 2025
Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference at gurufocus.com
3rd of January 2025
Acquisition by Paul Hastings of 94500 shares of Nkarta subject to Rule 16b-3 at MacroaxisInsider
2nd of January 2025
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635 at businesswire.com
2nd of January 2025
NextCure Shares Down 7.1 percent Heres Why at thelincolnianonline.com
31st of December 2024
Ikena Oncology Moves to Buy Rationale Behind the Upgrade - MSN at news.google.com
24th of December 2024
Ikena Oncologys Neutral Rating Reaffirmed at Wedbush at thelincolnianonline.com
23rd of December 2024
U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bios New Drug Appli... at businesswire.com
20th of December 2024
Acquisition by Celebi John of 355000 shares of Sensei Biotherapeutics at 0.4499 subject to... at MacroaxisInsider
19th of December 2024
Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing ... at finance.yahoo.com
19th of December 2024
StockNews.com Initiates Coverage on MediciNova at thelincolnianonline.com
18th of December 2024
Q2 2025 Champions Oncology Inc Earnings Call Transcript at gurufocus.com
18th of December 2024
SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineral... at news.google.com
18th of December 2024
Werewolf Therapeutics stock hits 52-week low at 1.58 - Investing.com at news.google.com
17th of December 2024
Foghorn Therapeutics Advances Precision Oncology Pipeline - Yahoo Finance at news.google.com
16th of December 2024
Philadelphia cell therapy developer loses Big Pharma partnership valued at over 3B at bizjournals.com
13th of December 2024
Wall Street Analysts Think Molecular Partners AG Sponsored ADR Could Surge 80.72 percent R... at finance.yahoo.com
13th of December 2024
3 Small-Cap Stocks With Big Growth Potential at marketbeat.com
12th of December 2024
Acquisition by Gay Jonathon of 30000 shares of Clene at 0.37 subject to Rule 16b-3 at MacroaxisInsider
12th of December 2024
After Plunging -30.17 percent in 4 Weeks, Heres Why the Trend Might Reverse for Foghorn Th... at finance.yahoo.com
11th of December 2024
Champions Oncology Reports Quarterly Revenue of 13.5 Million Adjusted EBITDA of 1.1 Millio... at finance.yahoo.com
10th of December 2024
FDA Provides Roadmap for Accelerated Approval Pathway Through Su at gurufocus.com
9th of December 2024
Kalamazoo a step closer to 30m payday after big drill results at thewest.com.au
6th of December 2024
Acquisition by Kiernan Matthew of 2853 shares of Clene at 4.4 subject to Rule 16b-3 at Kiernan Matthew
6th of December 2024
Nuvation Bio Shares Gap Down Heres Why at thelincolnianonline.com
5th of December 2024
Nkarta, Inc. Receives Average Rating of Buy from Brokerages at thelincolnianonline.com
2nd of December 2024
MediciNova stock undervalued D. Boral sees upside in ALS MS market opportunities at investing.com
29th of November 2024
Foghorn Therapeutics Upgraded to Buy Heres Why at zacks.com
27th of November 2024
Immunome, Inc. Insider Robert Lechleider Acquires 15,805 Shares at thelincolnianonline.com
26th of November 2024
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference at gurufocus.com
22nd of November 2024
MediciNova Stock Surges Amid Biotech Sector Momentum at gurufocus.com
20th of November 2024
ELYM Stock Earnings Eliem Therapeutics Reported Results for Q4 2023 - MSN at news.google.com
15th of November 2024
Clene Given Buy Rating at HC Wainwright at thelincolnianonline.com
15th of November 2024
Logos Global Management LP Reduces Stake in NextCure Inc at gurufocus.com
14th of November 2024
Kezar Life Sciences Given New 11.00 Price Target at Wells Fargo Company - MarketBeat at news.google.com
14th of November 2024
Werewolf Therapeutics Has Debt But No Earnings Should You Worry at simplywall.st
14th of November 2024
Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Hi... at globenewswire.com
13th of November 2024
Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights at globenewswire.com
13th of November 2024
Mineralys Therapeutics Releases Quarterly Earnings Results, Misses Estimates By 0.30 EPS at thelincolnianonline.com
12th of November 2024
Nkarta to Participate in an Upcoming Investor Conference at globenewswire.com
8th of November 2024
What Makes Century Therapeutics a New Buy Stock at zacks.com
8th of November 2024
Mineralys Therapeutics chief medical officer sells 383,065 in stock at investing.com
5th of November 2024
Century Therapeutics Non-GAAP EPS of -0.37 beats by 0.08, revenue of 0.8M beats by 0.25M at seekingalpha.com
5th of November 2024
Glancy Prongay Murray LLP Announces Investigation of Kezar Life Sciences, Inc. at businesswire.com
5th of November 2024
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC... at globenewswire.com
20th of September 2024
Disposition of tradable shares by Emily Pimblett of Eliem Therapeutics at 8.06 subject to ... at MacroaxisInsider
11th of September 2024
Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation S... at finance.yahoo.com
30th of June 2023
Cyteir Therapeutics Shares Jump percent After Plans to Dissolve Company at marketwatch.com
10th of May 2023
Should You Buy Graphite Bio Ahead of Earnings at zacks.com
2nd of May 2023
Catalyst to Report Q1 Earnings Whats in the Cards - Zacks Investment Research at news.google.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Clene in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Clene's short interest history, or implied volatility extrapolated from Clene options trading.
Check out Clene Backtesting and Clene Hype Analysis. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clene. If investors know Clene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.614 | Earnings Share (5.29) | Revenue Per Share | Quarterly Revenue Growth (0.66) | Return On Assets |
The market value of Clene Inc is measured differently than its book value, which is the value of Clene that is recorded on the company's balance sheet. Investors also form their own opinion of Clene's value that differs from its market value or its book value, called intrinsic value, which is Clene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clene's market value can be influenced by many factors that don't directly affect Clene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.